Limba
|
Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 KD.
Price | 9.330,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 KD. |